Is Palliative Care Bad? Debunking the 5 Biggest Myths

No. Palliative care is based on need, not on prognosis. It can begin at the point of diagnosis of a serious illness and run for months or years alongside active treatment. The landmark Temel NEJM 2010 study followed patients with metastatic lung cancer. Those who received early palliative care alongside standard oncology care actually had better quality of life, better mood, and longer median survival. 11.6 months versus 8.9 months. Many patients and families describe the first palliative care conversation as the moment hope became more realistic and useful, not the moment it ended.

In the large majority of properly managed cases, no. Palliative pain management is medically supervised and titrated for symptom control. Clinicians use validated risk screening tools, such as the Opioid Risk Tool. Ongoing monitoring balances effective pain relief against the risk of opioid-related harms5. The NICE guideline on strong opioids in palliative care explicitly recommends that clinicians ask patients and families about addiction concerns and discuss them openly. Pain in advanced illness is often undertreated because of exactly this fear, so raising it with your team is the right thing to do.

Yes. Palliative care teams work with patients and families, not around them, and decision-making authority stays with the patient throughout. Where capacity is reduced, authority transfers to a chosen decision-maker or family member, following any advance directives recorded earlier. Palliative care teams are usually the people who facilitate advance care planning early. The purpose: so the patient's own wishes continue to guide care if their condition progresses. The essential components of palliative care under the ASCO guideline include assistance with (not override of) medical decision-making.

No. The best clinical evidence shows the opposite pattern. The Temel 2010 NEJM study found that patients receiving early palliative care in metastatic lung cancer lived longer, not shorter. Median survival was 11.6 months versus 8.9 months in the standard care group. Subsequent evidence across cancer, heart failure, COPD and dementia populations consistently shows improved symptom burden, improved quality of life, and no evidence of shortened life. One likely explanation is that better symptom control, better mood, and better decision-making together let patients tolerate and benefit from active treatment more fully.